Multi-omics analyses of tumor-associated immune-infiltrating cells with the novel immune checkpoint protein tyrosine phosphatase 1B (PTP1B) in extracellular matrix of brain-lower-grade-glioma (LGG) and uveal-melanoma (UVM)

Bai, Kunhao; Zhu, Ming-Jiao; Zhang, Yiyang; Li, Xueping; Chen, Siliang; Wang, Dawei; Dai, Yong

doi:10.3389/fimmu.2022.1053856

Cited by 4 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A correlation was also found between increased expression of both TIGIT and indoleamine 2,3-dioxygenase (IDO) [ 75 ]. Protein tyrosine phosphatase 1B (PTP1B) [ 76 ] and tumor necrosis factor-alpha-induced protein-8 like 2 (TNFAIP8L2) [ 77 ] were found to be highly expressed in most tumors (including UM) and associated with poor prognosis in patients with UM. The latter was also found to significantly affect the tumor immune microenvironment, such as the stem cell index and dendritic cell infiltration.…”

Section: Current Status Of Clinical Studies Regarding Icis In Patient...mentioning

confidence: 99%

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review

Wang,

Li,

Yin

2024

Ophthalmol Ther

View full text Add to dashboard Cite

Introduction Immune checkpoint inhibitors have made tremendous progress over the last decade in the treatment of cutaneous melanoma, but their application in uveal melanoma treatment is less successful, owing in part to the immunological privilege of the eye and the liver, the most frequent site of metastasis. Nevertheless, the therapeutic outcomes reported currently are less pessimistic. Methods In this review, we provide an overview of recent studies of immune checkpoint inhibitors in uveal melanoma and its metastasis and classify studies in this field into three groups: monotherapy of immune checkpoint inhibitors, dual-agent immune checkpoint inhibitors, and immune checkpoint inhibitors combined with other systemic or regional therapies. Results Briefly, monotherapy with immune checkpoint inhibitors performed poorly. Dual-agent immune checkpoint inhibitors had slightly better outcomes than traditional treatments, especially in specific patient populations. As for the combination therapy, the combination with other systemic therapies did not show superiority over dual-agent immune checkpoint inhibitors, but combination with hepatic regional therapies was quite promising. Moreover, research on emerging checkpoints is currently limited to the stage of mechanistic studies. Conclusion We propose that immune checkpoint inhibitors remain alternative treatments for patients with uveal melanoma, but factors such as cost-effectiveness should also be taken into account. The combination therapy with immune checkpoint inhibitors deserves to be further explored.

show abstract

Section: Current Status Of Clinical Studies Regarding Icis In Patient...mentioning

confidence: 99%

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review

Wang,

Li,

Yin

2024

Ophthalmol Ther

View full text Add to dashboard Cite

show abstract

“…Genetic anomalies play a critical role in UVM development and progression [ 5 , 6 ]. Key genetic players, such as SF3B1 [ 6 ], PTP1B [ 7 ], BAP1 [ 8 ], and EIF1AX [ 9 ], serve both as indicators of prognosis and as therapeutic targets. While localized UVM cases have a promising 5-year survival rate of around 80%, metastatic instances often exhibit a dire prognosis, with an average survival duration of less than one year [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Tryptophan metabolism-related gene expression patterns: unveiling prognostic insights and immune landscapes in uveal melanoma

Wang,

Zhao,

et al. 2023

Aging

View full text Add to dashboard Cite

Uveal melanoma (UVM) remains the leading intraocular malignancy in adults, with a poor prognosis for those with metastatic disease. Tryptophan metabolism plays a pivotal role in influencing cancerous properties and modifying the tumor’s immune microenvironment. In this study, we explore the relationship between tryptophan metabolism-related gene (TRMG) expression and the various features of UVM, including prognosis and tumor microenvironment. Our analysis included 143 patient samples sourced from public databases. Using K-means clustering, we categorized UVM patients into two distinct clusters. Further, we developed a prognostic model based on five essential genes, effectively distinguishing between low-risk and high-risk patients. This distinction underscores the importance of TRMGs in UVM prognostication. Combining TRMG data with gender to create nomograms demonstrated exceptional accuracy in predicting UVM patient outcomes. Moreover, our analysis reveals correlations between risk assessments and immune cell infiltrations. Notably, the low-risk group displayed a heightened potential response to immune checkpoint inhibitors. In conclusion, our findings underscore the dynamic relationship between TRMG expression and various UVM characteristics, presenting a novel prognostic framework centered on TRMGs. The deep connection between TRMGs and UVM’s tumor immune microenvironment emphasizes the crucial role of tryptophan metabolism in shaping the immune landscape. Such understanding paves the way for designing targeted immunotherapy strategies for UVM patients.

show abstract